Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE37.7200
- TODAY'S CHANGE (%)0.0400 (0.1062%)
- Bid / Lots37.6100/ 4
- Ask / Lots37.7600/ 1
- Open / Previous Close37.5000 / 37.6800
- Day Range
- 52 Week Range
- Volume20,174
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 806 | 37.5 |
| 09:36 ET | 3561 | 37.66 |
| 09:43 ET | 100 | 37.395 |
| 09:45 ET | 100 | 37.395 |
| 09:52 ET | 626 | 37.57 |
| 09:54 ET | 6115 | 37.36 |
| 09:56 ET | 100 | 37.36 |
| 10:01 ET | 428 | 37.61 |
| 10:06 ET | 182 | 37.68 |
| 10:08 ET | 500 | 37.62 |
| 10:12 ET | 1200 | 37.43 |
| 10:14 ET | 1100 | 37.45 |
| 10:15 ET | 200 | 37.38 |
| 10:19 ET | 100 | 37.46 |
| 10:21 ET | 300 | 37.55 |
| 10:33 ET | 100 | 37.72 |
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -13.9x | --- |
MoonLake Immunotherapeutics | 2.7B | -55.9x | --- |
SpringWorks Therapeutics Inc | 3.0B | -7.7x | --- |
Biohaven Ltd | 3.1B | -5.0x | --- |
Structure Therapeutics Inc | 2.6B | -23.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
